REVIEW ARTICLE
Sepsis diagnosis and monitoring – procalcitonin as standard, but what next?
1
Department of Medical Biochemistry, Wroclaw Medical University, Poland
2
Department of Anesthesiology and Intensive Care, 4th Military Hospital of Wroclaw, Poland
3
Faculty of Health Science, Wroclaw Medical University, Poland
Publication date: 2019-09-25
Anaesthesiol Intensive Ther 2019;51(4):299-305
KEYWORDS
ABSTRACT
Sepsis is a life-threatening organ dysfunction caused by a systemic altered host response to infection. According to the newest guidelines the sepsis treatment should be personalized and based on an approach specified by use of biomarkers to tailor therapy to each patient’s needs. The main features of such biomarkers should be high specificity, sensitivity and ability to monitor the progress of sepsis. There is limited application of procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) for reaching this target, because of their secretion during non-infectious processes. The purpose of this review was to introduce four biomarkers, i.e. kallistatin, testican-1, presepsin and mid-regional pro-adrenomedullin, and compare their usefulness in diagnosing sepsis with PCT, CRP and IL-6.
REFERENCES (50)
1.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-810. doi: 10.1001/jama.2016.0287.
2.
Marshall JC, Reinhart K; International sepsis forum. Biomarkers of sepsis. Crit Care Med 2009; 37: 2290-2298. doi: 10.1097/CCM. 0b013e3181a02afc.
3.
Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence 2014; 5: 154-160. doi: 10.4161/viru.27393.
4.
Vijayan AL, Vanimaya, Ravindran S, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 2017; 5: 51. doi: 10.1186/s40560-017-0246-8.
5.
Dandona P, Nix D, Wilson WF. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-1608.
6.
Bloos F, Trips E, Nierhaus A, et al.; for SepNet Critical Care Trials Group: Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial. JAMA Intern Med 2016; 176: 1266-1276. doi: 10.1001/jamainternmed.2016.2514.
7.
Lelubre C, Anselin S, Zouaoui Boudjeltia K, Biston P, Piagnerelli M. Interpretation of C-reactive protein concentrations in critically ill patients. Biomed Res Int 2013; 2013: 124021. doi: 10.1155/2013/124021.
8.
Panacek EA, Kaul M. IL-6 as a marker of excessive TNF-α activity in sepsis. Sepsis 1999: 3: 65-73.
10.
Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 2000; 26: 1193-1200.
11.
Harbarth S, Holeckova K, Froidevaux C, et al.; Geneva Sepsis Network: Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.
12.
Chai KX, Chen LM, Chao J, Chao L. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem 1993; 268: 24498-24505.
13.
Chao J, Schmaier A, Chen LM, Yang Z, Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 1996; 127: 612-620.
14.
Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002; 100: 3245-3252.
15.
Chao J, Yin H, Yao YY, Shen B, Smith RS, Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006; 17: 1201-1213.
16.
Yin H, Gao L, Shen B, Chao L, Chao J. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappa-B activation. Hypertension 2010; 56: 260-267. doi: 10.1161/HYPERTENSIONAHA.110.152330.
17.
Li P, Bledsoe G, Yang ZR, Fan H, Chao L, Chao J. Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 2014; 142: 216-226. doi: 10.1111/imm.12242.
18.
Guo Y, Chao L, Chao J. Kallistatin attenuates endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway. J Cell Mol Med 2018; 22: 4387-4398. doi: 10.1111/jcmm.13734.
19.
Chao J, Bledsoe G, Chao L. Protective role of kallistatin in vascular and organ injury. Hypertension 2016; 68: 533-541. doi: 10.1161/HYPERTENSIONAHA.116.07861.
20.
Lin WC, Lu SL, Lin CF, et al. Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care 2013; 17: R27. doi: 10.1186/cc12507.
21.
Lin WC, Chen CW, Chao L, Chao J, Lin YS. Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS ONE 2017; 12: e0178387. doi: 10.1371/journal.pone.0178387.
22.
Li P, Guo Y, Bledsoe G, et al. Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care 2015; 19: 200. doi: 10.1186/s13054-015-0919-4.
23.
Charbonnier F, Chanoine C, Cifuentes-Diaz C, et al. Expression of the proteoglycan SPOCK during mouse embryo development. Mech Devt 2000; 90: 317-321.
24.
Marr HS, Edgell CJ. Testican-1 inhibits attachment of Neuro-2a cells. Matrix Biol 2003; 22: 259-266.
25.
Bonnet F, Périn JP, Charbonnier F, et al. Structure and cellular distribution of mouse brain testican. Association with the postsynaptic area of hippocampus pyramidal cells. J Biol Chem 1996; 271: 565-569.
26.
Nakada M, Yamada A, Takino T, et al. Suppression of membrane-type 1 matrix metalloprinase (MMP)-mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes. Cancer Res 2001; 61: 8896-8902.
27.
Lee Y, Lee W, Chang HH, et al. Testican-1, as a novel diagnosis of sepsis. J Cell Biochem 2018; 119: 4216–4223. doi: 10.1002/jcb.26661.
28.
Gruda MC, Ruggeberg KG, O’Sullivan P, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads. PLoS ONE 2018; 13: e0191676. doi: 10.1371/journal.pone.0191676.
29.
Park B, Lee J. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 2013; 45: e66. doi: 10.1038/emm.2013.97.
30.
Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med 2014; 5: 16-19. doi: 10.5847/wjem.j.1920- 8642.2014.01.002.
31.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011; 17: 764-769. doi: 10.1007/s10156-011-0254-x.
32.
Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011; 412: 2157-2161. doi: 10.1016/j.cca.2011.07.024.
33.
Wu CC, Lan HM, Han ST, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systemic review and meta-analysis. Ann Intensive Care 2017; 7: 91. doi: 10.1186/s13613-017-0316-z.
34.
Shirakawa K, Naitou K, Hirose J, Takahashi T, Furusako S. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med 2011; 49: 937-939. doi: 10.1515/CCLM.2011.145.
35.
Tong X, Cao Y, Yu M, Han C. Presepsin as a diagnostic marker for sepsis: evidence from a bivariate meta-analysis. Ther Clin Risk Manag 2015; 11: 1027–1033. doi: 10.2147/TCRM.S84811.
36.
Endo S, Suzuki Y, Takahashi G, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J Infect Chemother 2014; 20: 30-34. doi: 10.1016/j.jiac.2013.07.005.
37.
Wu J, Hu L, Zhang G, Wu F, He T. Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0133057. doi: 10.1371/journal.pone.0133057.
38.
Yang HS, Hur M, Yi A, Kim H, Lee S, Kim SN. Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis. PLoS One 2018; 13: e0191486. doi: 10.1371/journal.pone.0191486.
39.
Matera G, Quirino A, Peronace C, et al. Soluble CD14 subtype-a new biomarker in predicting the outcome of critically ill septic patients. Am J Med Sci 2017; 353: 543-551. doi: 10.1016/j.amjms.2017.03.036.
40.
Kitamura K, Kangawa K, Kawamoto M et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
41.
Kato J, Kitamura K. Bench-to-bedside pharmacology of adrenomedullin. Eur J Pharmacol 2015; 764: 140-148. doi: 10.1016/j.ejphar. 2015.06.061.
42.
Geven C, Kox M, Pickkers P. Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis. Front Immunol 2018; 9: 292. doi: 10.3389/fimmu.2018.00292.
43.
Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004; 25: 1369-1372.
44.
Henriquez-Camacho C, Losa J. Biomarkers for sepsis. Biomed Res Int 2014; 2014: 547818. doi: 10.1155/2014/547818.
45.
Temmesfeld-Wollbrück B, Hocke AC, Suttorp N, Hippenstiel S. Adrenomedullin and endothelial barrier function. Thromb Haemost 2007; 98: 944-951.
46.
Gonzales-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. Am J Pathol 2006; 168: 1921- 1930.
47.
Elke G, Bloos F, Wilson DC, et al.; SepNet Critical Care Trials Group: The use of mild-regional proadrenomedullin to identify disease severity and treatment response to sepsis-a secondary analysis of a large randomized controlled trial. Crit Care 2018; 22: 79. doi: 10.1186/s13054-018-2001-5.
48.
Enguix-Armada A, Escobar-Conesa R, García-De La Torre A, De La Torre-Prados MV. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med 2016; 54: 163–168. doi: 10.1515/cclm-2015-0243.
49.
Mebazaa A, Geven C, Hollinger A, et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care 2018; 22: 354. doi: 10.1186/s13054-018-2243-2.
50.
Geven C, Blet A, Kox M, et al. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). BMJ Open 2019; 9: e024475. doi: 10.1136/bmjopen-2018-024475.
| eISSN: | 1731-2531 |
| ISSN: | 1642-5758 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
